Influence of Simvastatin on Aspects of Thrombogenesis in CAPD Patients
暂无分享,去创建一个
[1] R. Rigby,et al. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] Masayoshi Hashimoto,et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days , 2002 .
[3] J. Małyszko,et al. Effects of Long-Term Treatment with Simvastatin on Some Hemostatic Parameters in Continuous Ambulatory Peritoneal Dialysis Patients , 2001, American Journal of Nephrology.
[4] A. Åsberg,et al. Atorvastatin improves endothelial function in renal‐transplant recipients , 2001 .
[5] G. Lip,et al. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. , 2001, The American journal of cardiology.
[6] G. Lip,et al. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. , 2001, The American journal of cardiology.
[7] K. Mann,et al. Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation , 2001, Circulation.
[8] J. Dvořáková,et al. Effect of pravastatin on plasma concentrations of homocysteine in primary hypercholesterolemia , 2001 .
[9] A. Åsberg,et al. Atorvastatin improves endothelial function in renal-transplant recipients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] J. Małyszko,et al. Comparison of Hemostatic Disturbances between Patients on Capd and Patients on Hemodialysis , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[11] G. Davı̀,et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. , 2000, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[12] R. Blumenthal. Statins: effective antiatherosclerotic therapy. , 2000, American heart journal.
[13] N. Yorioka,et al. Lipid-Lowering Therapy and Coagulation/Fibrinolysis Parameters in Patients on Peritoneal Dialysis , 2000, The International journal of artificial organs.
[14] J. Harenberg,et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. , 1999, Thrombosis research.
[15] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[16] F. Vrtovsnik,et al. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. , 1998, Journal of the American Society of Nephrology : JASN.
[17] R. Rosenson,et al. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.
[18] G. Avellone,et al. INCREASED THROMBIN GENERATION AND COMPLEMENT ACTIVATION IN PATIENTS WITH TYPE IIA HYPERLIPOPROTEINEMIA: EFFECTS OF SIMVASTATIN TREATMENT , 1997 .
[19] D. Green,et al. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. , 1997, Circulation.
[20] F. Marumo,et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[21] C. Ballantyne,et al. Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia , 1996 .
[22] T. Shigematsu,et al. Is Atherosclerosis Accelerated by Capd? , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[23] M. Elisaf,et al. Lipid Parameters Including Lipoprotein (A) in Patients Undergoing CAPD and Hemodialysis , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[24] R. Wolfe,et al. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.
[25] R. Knöfler,et al. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. , 1994, Thrombosis research.
[26] K. Kario,et al. Increased Tissue Factor Pathway Inhibitor Levels in Uremic Patients on Regular Hemodialysis , 1994, Thrombosis and Haemostasis.
[27] B. Scribner,et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. , 1974, The New England journal of medicine.
[28] G. Born,et al. Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.
[29] S. Niewiarowski,et al. AN EVALUATION OF THE EUGLOBULIN METHOD FOR THE DETERMINATION OF FIBRINOLYSIS , 1959, Journal of clinical pathology.
[30] G. Habib,et al. Fluvastatin Decreases Soluble Thrombomodulin in Cardiac Transplant Recipients , 2000, Thrombosis and Haemostasis.
[31] T. Hayek,et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. , 1998, Journal of cardiovascular pharmacology.
[32] N. Yorioka,et al. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. , 1997, Nephron.
[33] G. Barsotti,et al. Bleeding and thrombosis in chronic uremia. , 1997, Nephron.
[34] A. Gotto,et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. , 1996, Circulation.
[35] W. Keane,et al. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. , 1996, Mineral and electrolyte metabolism.
[36] J. Małyszko,et al. Original Article: Cyclosporine a and FK 506 Affect Platelet Functions in Vitro. , 1995, Platelets.